Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $82000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 2.38% to $82000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $327000.0 through Dec 2025, up 6.17% year-over-year, with the annual reading at $327000.0 for FY2025, 6.17% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $82000.0 at Orchestra BioMed Holdings, up from $81000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $84000.0 in Q4 2024, with the low at $48000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 4 years is $71500.0, with a median of $73500.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) soared 47.92% in 2023, then decreased 2.38% in 2025.
  • Over 4 years, Depreciation & Amortization (CF) stood at $70000.0 in 2022, then increased by 2.86% to $72000.0 in 2023, then grew by 16.67% to $84000.0 in 2024, then fell by 2.38% to $82000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $82000.0, $81000.0, and $81000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.